Study guide
3.3 Psychopharmacology and Substance Effects
EPPP Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Orientation: EPPP Two-Part Exam, Eligibility, Fees, Authorization, Scoring, and Retakes
1.1 Two-Part 2026 EPPP and the Candidate Handbook 1.2 Jurisdiction Eligibility and Authorization to Test 1.3 Fees and Budget Control 1.4 Pearson VUE Appointments, Timing, and Identification 1.5 Scaled Scoring and Passing Recommendations 1.6 Retakes, Remediation, and Board Follow-Up
2 Part 1 and Part 2 Domain Map, Pretest Items, Pacing, and Study Strategy
2.1 Part 1-Knowledge Domain Map 2.2 Part 2-Skills Domain Map 2.3 Pretest Items and Exam Development 2.4 Timing, Pacing, and Review Discipline 2.5 Domain Weighting and Score Equating 2.6 Study Strategy Across Both Parts
3 Biological Bases and Cognitive-Affective Bases of Behavior
3.1 Part 1 Map for Biological and Cognitive-Affective Bases 3.2 Neuroanatomy, Neurotransmission, and Imaging 3.3 Psychopharmacology and Substance Effects 3.4 Genetics, Epigenetics, Endocrine Systems, and Health Behavior 3.5 Attention, Learning, Memory, and Executive Function 3.6 Emotion, Motivation, Stress, and Affect-Behavior Links
4 Social/Cultural Bases and Growth/Lifespan Development
4.1 Part 1 Map for Social/Cultural and Lifespan Domains 4.2 Social Cognition, Attitudes, and Attribution 4.3 Groups, Social Influence, and Relationships 4.4 Culture, Diversity, Identity, and Clinical Reasoning 4.5 Lifespan Theories, Developmental Tasks, and Aging 4.6 Risk, Protective Factors, and Developmental Psychopathology
5 Assessment and Diagnosis: Psychometrics, Differential Diagnosis, and Communication
5.1 Assessment Domain Orientation for EPPP Part 1 5.2 Psychometric Foundations: Reliability, Validity, Norms, and Error 5.3 Clinical Interviewing, Mental Status, Collateral Data, and Risk 5.4 Diagnostic Frameworks and Differential Diagnosis 5.5 Test Selection, Administration, Scoring, and Interpretation 5.6 Diversity-Responsive Assessment and Fair Interpretation 5.7 Assessment Reports, Feedback, and Communication of Findings
6 Treatment, Intervention, Prevention, Consultation, and Supervision Knowledge
6.1 Treatment Domain Orientation and Evidence-Based Practice 6.2 Case Formulation and Treatment Planning 6.3 Major Intervention Models and Mechanisms of Change 6.4 Prevention, Crisis Intervention, and Risk Management 6.5 Consultation, Interprofessional Work, and Systems Practice 6.6 Supervision Models, Competence, Evaluation, and Telepsychology
7 Research Methods, Statistics, and Evidence-Based Practice
7.1 Research Domain Map and Exam Logic 7.2 Designs, Sampling, and Variable Control 7.3 Measurement, Reliability, and Validity 7.4 Validity Threats and Causal Inference 7.5 Descriptive, Inferential, and Predictive Statistics 7.6 Effect Size, Power, Clinical Significance, and Program Evaluation
8 Ethical, Legal, and Professional Issues for Part 1
8.1 Ethics Domain, Sources, and Decision Model 8.2 Competence, Scope, Impairment, Consultation, and Referral 8.3 Informed Consent, Confidentiality, Privacy, and Records 8.4 Boundaries, Multiple Relationships, Conflicts, and Fees 8.5 Assessment, Intervention, Supervision, and Evidence Ethics 8.6 Telepsychology, Emerging Issues, Rights, and Jurisdiction
9 Part 2 Skills I: Scientific Orientation, Assessment, and Intervention
9.1 Scientific Orientation in Real Practice Decisions 9.2 Critical Appraisal and Evidence Fit 9.3 Assessment Method Selection and Measurement Planning 9.4 Interviewing, Observation, Collateral Data, and Diagnosis 9.5 Risk Assessment, Safety Planning, and Crisis Decisions 9.6 Intervention Planning, Adaptation, and Informed Consent 9.7 Progress Monitoring, Outcomes, and Course Correction
10 Part 2 Skills II: Relational Competence, Professionalism, and Ethical Practice
10.1 Relational Competence, Alliance, and Boundaries 10.2 Diversity, Culture, Language, and Bias in Practice 10.3 Self-Reflection, Competence, and Professional Limits 10.4 Professional Responsibility, Records, and Practice Management 10.5 Ethical Documentation, Consent, and Confidentiality 10.6 Billing, Multiple Relationships, and Ethical Consultation
11 Part 2 Skills III: Collaboration, Consultation, Supervision, and Systems Practice
11.1 Interdisciplinary Collaboration, Role Clarity, and Shared Decisions 11.2 Consultation Models, Referral Questions, and Boundaries 11.3 Supervision Structure, Alliance, Feedback, and Gatekeeping 11.4 Supervisee Compliance, Documentation, and Risk Response 11.5 Systems Practice, Program Evaluation, and Quality Improvement 11.6 Integrated Part 2 Decision Practice for Collaboration and Systems
12 Final EPPP Review: Test Day, Results, Score Transfer, and Licensure Next Steps
12.1 Final Two-Part Review and Official Fact Check 12.2 Authorization, Scheduling, Fees, and Identification 12.3 Test-Day Timing, Tutorial, Survey, and Pacing 12.4 Results, Scaled Scores, Feedback, and Score Meaning 12.5 Retakes, Score Transfer, and Board Follow-Up 12.6 Jurisprudence, Supervised Experience, and the Final Licensure File
3.3 Psychopharmacology and Substance Effects
Key Takeaways Explain This Topic AI
Psychologists must recognize drug classes, intended effects, adverse effects, adherence barriers, and referral limits.
EPPP items test coordination and risk recognition far more than prescribing detail (most states do not grant RxP).
Intoxication, withdrawal, tolerance, and drug interactions can mimic or worsen psychiatric and cognitive disorders.
Strong answers protect scope while promoting safety, informed collaboration, and continuity of care.
Last updated: June 2026
Medication knowledge without exceeding scope
EPPP psychopharmacology items usually ask what a psychologist should recognize, assess, document, communicate, or refer — not how to prescribe. Prescriptive authority (RxP) exists for specially trained psychologists in only a small number of jurisdictions (for example New Mexico, Louisiana, Illinois, Iowa, Idaho, and a few others); most psychologists do not prescribe. The exam still expects you to know that medications and substances affect mood, cognition, sleep, movement, motivation, risk, and treatment engagement.
Study classes by clinical purpose and common concern rather than memorizing every brand name.
Class Examples High-yield adverse effects
SSRIs / SNRIs fluoxetine, sertraline, venlafaxine Activation, sexual dysfunction, GI upset, possible early suicidality in youth, serotonin syndrome if combined
Antipsychotics haloperidol (typical), risperidone, olanzapine (atypical) Extrapyramidal symptoms, tardive dyskinesia, metabolic syndrome, sedation, prolactin elevation
Mood stabilizers lithium, valproate, lamotrigine Lithium toxicity (narrow therapeutic window, needs blood monitoring), tremor, rash (lamotrigine)
Stimulants / nonstimulants methylphenidate, amphetamine, atomoxetine Appetite/sleep loss, raised heart rate/BP, diversion/abuse risk
Anxiolytics / sedative-hypnotics benzodiazepines, zolpidem Sedation, dependence, falls, dangerous interaction with alcohol/opioids
Key watch-outs the EPPP favors: lithium requires serum monitoring because therapeutic and toxic levels are close; monoamine oxidase inhibitors (MAOIs) require a tyramine-restricted diet to avoid hypertensive crisis; serotonin syndrome (agitation, hyperthermia, clonus) can follow serotonergic combinations; and abrupt benzodiazepine or alcohol withdrawal can cause seizures and is medically dangerous.
Substance effects in the differential
Intoxication can produce mood, anxiety, psychotic, cognitive, and behavioral symptoms. Withdrawal can create insomnia, irritability, dysphoria, tremor, agitation, confusion, or medical danger. Tolerance means the same dose produces a smaller effect; dependence involves physiological adaptation; and substance-induced symptoms must be ruled out before settling on a primary psychiatric diagnosis (for example, a stimulant or cannabis-driven anxiety presentation, or alcohol-related depression).
Issue Why it matters Appropriate psychologist action
Adverse effects Can reduce adherence or mimic symptoms. Assess, document, encourage prescriber contact, coordinate care.
Activation / sedation Affects sleep, driving, work, and safety. Screen timing, severity, and functional impact.
Substance use Alters diagnosis and treatment response. Assess pattern, last use, risk, and referral need.
Interactions Combinations can be dangerous. Ask nonjudgmentally; collaborate within consent and law.
Adherence is psychological
Clients stop medication because of side effects, cost, stigma, cultural beliefs, pregnancy concerns, mistrust, low insight, cognitive impairment, or poor prescriber communication. A strong answer explores barriers and supports informed decision-making rather than scolding.
Scenario pattern. A client on an antipsychotic reports new restlessness and inability to sit still. The strong response considers akathisia , assesses distress and safety, and coordinates with the prescriber rather than labeling the client noncompliant. Scenario pattern. A client with panic uses heavy caffeine and intermittent cannabis; assess substance timing because both can trigger anxiety, while still considering panic disorder, trauma, and medical causes.
Scope reminders:
Do not start, stop, or change medication unless legally authorized and competent.
Do ask about drug name, reported dose, timing, adherence, perceived benefits, side effects, and prescriber contact.
Do push for urgent care when symptoms suggest overdose, severe reaction, withdrawal risk, or imminent danger.
Do obtain releases for coordination while respecting confidentiality and jurisdictional law.
Pharmacokinetics and special populations
The EPPP expects broad awareness of how the body handles drugs. Pharmacokinetics (absorption, distribution, metabolism, excretion) explains why dosing varies; hepatic metabolism via cytochrome P450 enzymes is the basis of many interactions. Pharmacodynamics concerns the drug's effect at receptors (agonist, antagonist, partial agonist). Older adults often need lower doses because of slowed metabolism and heightened sensitivity (especially to anticholinergic and sedative effects, which raise fall and delirium risk).
Children and adolescents carry specific warnings — for example, the boxed warning about increased suicidal thinking with antidepressants in youth, which makes monitoring essential. Pregnancy and lactation add risk-benefit complexity that belongs with the prescriber, though the psychologist should know to raise the question.
Recognizing dangerous syndromes
A handful of medication emergencies recur on the exam. Neuroleptic malignant syndrome (high fever, rigidity, altered mental status, autonomic instability) is a rare but life-threatening antipsychotic reaction requiring emergency care. Serotonin syndrome (agitation, hyperthermia, tremor, clonus) follows excess serotonergic activity. Lithium toxicity (coarse tremor, confusion, ataxia, vomiting) can be fatal. The correct psychologist response to any of these is urgent medical referral, not watchful waiting. Recognizing the pattern and acting on it — rather than knowing the precise pharmacology — is what items reward.
Even though this chapter teaches Part 1 knowledge, Part 2-Skills items reuse the same reasoning: how to communicate a medication concern, consult, document risk, secure informed consent, or adapt treatment when biological variables affect functioning. The throughline is that recognition plus appropriate coordination, inside scope, is almost always the keyed answer.
A final exam tip: when a stem offers an option to act unilaterally on medication (telling a client to stop, increase, or skip a dose) and another to consult the prescriber, the consult option is nearly always correct for a non-prescribing psychologist. When a stem describes a possible overdose, severe reaction, or withdrawal seizure risk, the emergency-referral option outranks any therapeutic interpretation. Reading carefully for these safety and scope cues lets candidates eliminate two or three distractors quickly, even on items where the underlying pharmacology is unfamiliar.